0
0
New Delhi, June 26:
A major international investigation has revealed that several chemotherapy drugs produced by Indian pharmaceutical companies have failed critical quality tests, putting cancer patients in over 100 countries at risk. The findings, published by the Bureau of Investigative Journalism (TBIJ) in collaboration with the University of Notre Dame, highlight alarming lapses in the efficacy and safety of drugs central to the treatment of breast cancer, ovarian cancer, and various forms of leukemia.
Key Findings: Unsafe Dosages and Widespread Impact
-
Nearly 1 in 5 samples of seven essential chemotherapy drugs—such as cisplatin, methotrexate, and cyclophosphamide—failed international potency standards, according to the study that analyzed 189 samples from pharmacies in Africa and Asia.
-
Some drugs contained less than 88% of the stated active ingredient, rendering them ineffective, while others exceeded 112%, posing a risk of severe organ damage or death.
-
The majority of the failed drugs (16 out of 17 manufacturers) were traced to Indian companies, underscoring a systemic issue in the world’s largest exporter of generic medicines.
Consequences for Patients and Health Systems
Doctors in multiple countries reported that patients who initially responded to chemotherapy later showed no improvement or suffered unexpected, toxic side effects. In some cases, the lack of typical side effects (such as nausea or hair loss) led oncologists to question whether patients were receiving effective treatment at all.
The failure of first-line therapies often forced doctors to switch patients to more expensive, less effective alternatives, further straining already limited healthcare resources in low- and middle-income countries.
Industry and Regulatory Response
Indian pharmaceutical firms, including Venus Remedies and Zee Laboratories—whose drugs repeatedly failed potency tests—have disputed the findings, attributing quality issues to poor storage conditions rather than manufacturing faults. However, the study’s authors have defended their methodology, noting that the testing was peer-reviewed and adhered to international standards.
India’s drug regulator stated that substandard drugs are recalled and manufacturers face penalties or legal action. Yet, critics argue that regulatory enforcement remains inadequate, with some flagged companies continuing to export globally.
Global Repercussions and Calls for Reform
India’s reputation as the “pharmacy of the world” is now under scrutiny. Public health experts warn that these revelations could erode trust in generic medicines, which millions rely on for affordable cancer care. There are growing calls for stricter enforcement, real-time quality monitoring, and increased transparency in pharmaceutical production.
Industry and Government Silence
As of publication, the Indian pharmaceutical industry and government officials have not issued an official statement addressing the investigation’s findings. Sources suggest that a probe into the quality control practices of implicated firms may be imminent.
“Both scenarios are horrendous,” said a pharmacist involved in the investigation. “It’s heartbreaking.”
Disclaimer:
This article is based on findings from an international investigation by the Bureau of Investigative Journalism and the University of Notre Dame, as reported by multiple news outlets. The information reflects the results and interpretations of these studies and investigations. The Indian pharmaceutical companies named have disputed some of the findings, and regulatory reviews are ongoing. Readers are advised to consult healthcare professionals and regulatory authorities for the most current and comprehensive information regarding medication safety and efficacy.
